New hope for boys with devastating muscle disease
NCT ID NCT07250737
Summary
This program provides access to an experimental drug called AOC 1044 for people with Duchenne muscular dystrophy who have specific genetic mutations. The treatment aims to help produce a functional version of the dystrophin protein that's missing in this disease. Eligible participants must be at least 6 years old and have the specific genetic mutation that responds to this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENETIC DISEASES, INBORN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Children's Hospital
AVAILABLELittle Rock, Arkansas, 72202, United States
-
Gillette Children's
AVAILABLESaint Paul, Minnesota, 55101, United States
-
Rare Disease Research
AVAILABLEAtlanta, Georgia, 30329, United States
Conditions
Explore the condition pages connected to this study.